<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02086175</url>
  </required_header>
  <id_info>
    <org_study_id>13-398</org_study_id>
    <nct_id>NCT02086175</nct_id>
  </id_info>
  <brief_title>A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HiberCell, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is evaluating a drug combination called Imprime PGG and Rituximab as a&#xD;
      possible treatment for relapsed/refractory indolent B cell non-Hodgkin lymphomas (NHL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After the screening procedures confirms eligibility:&#xD;
&#xD;
      Study Drugs: The participant will receive both Imprime PGG and rituximab weekly, for four&#xD;
      weeks.&#xD;
&#xD;
      Clinical Exams: At the participant's weekly visit there will be have a physical exam and&#xD;
      general health and specific questions about any problems they might be having and any&#xD;
      medications the participant may be taking.&#xD;
&#xD;
      Scans (or Imaging tests):The Investigator will measure the participant's tumor 10 weeks after&#xD;
      Week 4 of treatment by CT scan. Additional scans will be performed at 6 months and 12 months&#xD;
      following the end of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">February 1, 2021</completion_date>
  <primary_completion_date type="Actual">October 11, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Response assessed at week 14 of study calendar (10 weeks after the 4-week treatment regimen).</time_frame>
    <description>Overall response rate is percentage of participants with complete (CR) and partial (PR) responses as best response during treatment.&#xD;
CR:&#xD;
Nodal Masses:&#xD;
For FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative&#xD;
For variably FDG-avid or PET negative; regression to normal size on CT.&#xD;
Liver/Spleen:&#xD;
No palpable nodules&#xD;
-Bone Marrow Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative.&#xD;
PR:&#xD;
Nodal Masses:&#xD;
50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes.&#xD;
FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site.&#xD;
Variably FDG-avid or PET negative; regression on CT.&#xD;
Liver/Spleen:&#xD;
50% decrease in SPD of nodules; no increase in size of liver or spleen.&#xD;
Bone Marrow:&#xD;
Irrelevant if positive prior to therapy; cell type should be specified.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Progression-free Survival (PFS)</measure>
    <time_frame>Patients were followed for a median (range) of 13.6 months (3-25).</time_frame>
    <description>Progression free survival (PFS) is defined as the time from start of treatment to disease progression or death from any cause as estimated by Kaplan Meier methods. Patients who have not progressed and are alive are censored at the date the patient is known to be progression-free. Response is measure using the International Harmonization Project for Lymphoma criteria Cheson 2007, using CT scans of the chest, abdomen, and pelvis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Patients were followed for a median (range) of 13.6 months (3-25).</time_frame>
    <description>Duration of response DR is defined as the time from the date of first response (complete or partial) after treatment to the date of disease progression or death for any cause. Patients who are alive without progression are censored at the date the patient is last know to be progression-free.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of Post-treatment Imprime PGG-bound Neutrophils With Response</measure>
    <time_frame>Up to 14 weeks with a median (range of) 13 weeks (12-14).</time_frame>
    <description>Imprime PGG-bound neutrophils analyzed using established methods (peripheral blood samples and post-treatment tumor samples to quantify the binding of Imprime PGG to neutrophils) combined with treatment response, best response.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas</condition>
  <arm_group>
    <arm_group_label>Imprime PGG and Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study drug, Imprime PGG, will be administered intravenously at a dose of 4mg/kg weekly for 4 weeks. Rituximab will be administered intravenously by institutional standards concurrently at a dose of 375mg/m2 weekly for 4 weeks. Response will be assessed with CT scans 10 weeks +/- 3 days following the completion of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imprime PGG</intervention_name>
    <arm_group_label>Imprime PGG and Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Imprime PGG and Rituximab</arm_group_label>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Mabthera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must meet the following criteria on screening examination to be eligible&#xD;
             to participate in the study:&#xD;
&#xD;
          -  Patients must have histologically determined indolent NHL that is relapsed or primary&#xD;
             refractory after initial therapy. Indolent NHL includes the morphologic and clinical&#xD;
             variants:&#xD;
&#xD;
               -  Follicular lymphoma, grades 1-3a&#xD;
&#xD;
               -  Marginal zone lymphoma (extranodal, nodal, or splenic)&#xD;
&#xD;
                    -  All nodal marginal zone lymphomas are eligible&#xD;
&#xD;
                    -  Extranodal marginal zone lymphomas of the stomach (gastric MALT lymphomas)&#xD;
                       may not be candidates for cure with antibiotics or local radiotherapy.&#xD;
                       Patients who have failed antibiotics or local therapy are eligible for the&#xD;
                       protocol as long as they have measurable disease and are naïve to&#xD;
                       chemotherapy and monoclonal antibody therapy.&#xD;
&#xD;
                    -  Splenic marginal zone lymphoma patients may have received prior splenectomy&#xD;
                       as long as they have measurable disease and are naïve to chemotherapy and&#xD;
                       monoclonal antibody therapy.&#xD;
&#xD;
               -  Re-biopsy is not mandated at relapse unless there is clinical suspicion about an&#xD;
                  alternate diagnosis.&#xD;
&#xD;
          -  Between 1-3 prior lines of chemoimmunotherapy and/or monotherapy with rituximab.&#xD;
             Patients may not have had prior autologous or allogeneic stem cell transplantation.&#xD;
&#xD;
          -  Measurable disease that has not been previously irradiated on CT scans of at least 2&#xD;
             cm, OR if the patient has had previous radiation to the marker lesion(s), there must&#xD;
             be evidence of progression since the radiation. Imaging must be completed no greater&#xD;
             than 4 weeks prior to study enrollment.&#xD;
&#xD;
          -  ECOG performance status 0-2 (Appendix B, Section 17.2)&#xD;
&#xD;
          -  Absolute neutrophil count ≥1000 prior to treatment&#xD;
&#xD;
          -  Oxygen saturation ≥ 90%, no more than 2 LPM oxygen&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 X ULN&#xD;
&#xD;
          -  AST ≤ 3 X ULN&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 X ULN (unless there is lymphoma in the liver)&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who exhibit any of the following conditions at screening will not be&#xD;
             eligible for admission into the study.&#xD;
&#xD;
          -  Patients currently receiving anticancer therapies or who have received anticancer&#xD;
             therapies within 30 days of the start of study drug (including chemotherapy, radiation&#xD;
             therapy, antibody based therapy, etc.). Steroids for symptom palliation are allowed,&#xD;
             but must be either discontinued or on stable doses at the time of initiation of&#xD;
             protocol therapy.&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents, or have received&#xD;
             investigational agents within 4 weeks of beginning treatment.&#xD;
&#xD;
          -  Patients who have previously received PGG-Betafectin (Betafectin®) or Imprime PGG.&#xD;
&#xD;
          -  Patients, who have had a major surgery or significant traumatic injury within 4 weeks&#xD;
             of start of study drug, patients who have not recovered from the side effects of any&#xD;
             major surgery (defined as requiring general anesthesia) or patients that may require&#xD;
             major surgery during the course of the study.&#xD;
&#xD;
          -  Patients with known leptomeningeal or brain metastases. Imaging or spinal fluid&#xD;
             analysis to exclude CNS involvement is not required, unless there is clinical&#xD;
             suspicion by the treating investigator.&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or&#xD;
             a known hypersensitivity to baker's yeast.&#xD;
&#xD;
          -  Patients with known HIV infection or hepatitis B or C infection.HIV testing is not&#xD;
             mandated and is to be performed at the discretion of the treating investigator.&#xD;
&#xD;
          -  Patients with a systemic fungal, bacterial, viral, or other infection not controlled&#xD;
             (defined as exhibiting ongoing signs/symptoms related to the infection and without&#xD;
             improvement, despite appropriate antibiotics or other treatment).&#xD;
&#xD;
          -  Prior history of another malignancy (except for non-melanoma skin cancer or in situ&#xD;
             cervical or breast cancer) unless disease free for at least three years. Patients with&#xD;
             prostate cancer are allowed if PSA is less than 1.&#xD;
&#xD;
          -  Patients should not receive immunization with attenuated live vaccine within one week&#xD;
             of study entry or during study period.&#xD;
&#xD;
          -  Female patients who are pregnant or breast feeding, or adults of reproductive&#xD;
             potential who are not using effective birth control methods. Women of child bearing&#xD;
             potential (WOCBP) or male study participants of reproductive potential must agree to&#xD;
             use double barrier birth control method of contraception during the course of the&#xD;
             study treatment period and for 3 months after completing study treatment.&#xD;
&#xD;
             -- WOCBP are defined as sexually mature women who have not undergone a hysterectomy or&#xD;
             who are not postmenopausal (no menses) for at least 12 consecutive months. WOCBP must&#xD;
             have a negative urine or serum pregnancy test within 7 days prior to administration of&#xD;
             treatment.&#xD;
&#xD;
          -  History of noncompliance to medical regimens.&#xD;
&#xD;
          -  Patients who have any severe and/or uncontrolled medical conditions or other&#xD;
             conditions that could affect their participation in the study such as:&#xD;
&#xD;
               -  New York Heart Association Class III or IV cardiac disease, including&#xD;
                  pre-existing clinically significant arrhythmia, congestive heart failure, or&#xD;
                  cardiomyopathy&#xD;
&#xD;
               -  unstable angina pectoris, symptomatic congestive heart failure, myocardial&#xD;
                  infarction within 6 months of start of study drug, serious uncontrolled cardiac&#xD;
                  arrhythmia or any other clinically significant cardiac disease&#xD;
&#xD;
          -  Other uncontrolled intercurrent illness that would limit adherence to study&#xD;
             requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caron Jacobson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 11, 2014</study_first_submitted>
  <study_first_submitted_qc>March 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2014</study_first_posted>
  <results_first_submitted>August 4, 2020</results_first_submitted>
  <results_first_submitted_qc>December 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 7, 2021</results_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Caron A. Jacobson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>relapsed/refractory indolent B cell non-Hodgkin lymphomas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data can be shared no earlier than 1 year following the date of publication</ipd_time_frame>
    <ipd_access_criteria>DFCI - Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT02086175/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Imprime PGG and Rituximab</title>
          <description>The study drug, Imprime PGG, will be administered intravenously at a dose of 4mg/kg weekly for 4 weeks. Rituximab will be administered intravenously by institutional standards concurrently at a dose of 375mg/m2 weekly for 4 weeks. Response will be assessed with CT scans 10 weeks +/- 3 days following the completion of treatment&#xD;
Imprime PGG&#xD;
Rituximab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Imprime PGG and Rituximab</title>
          <description>The study drug, Imprime PGG, will be administered intravenously at a dose of 4mg/kg weekly for 4 weeks. Rituximab will be administered intravenously by institutional standards concurrently at a dose of 375mg/m2 weekly for 4 weeks. Response will be assessed with CT scans 10 weeks +/- 3 days following the completion of treatment&#xD;
Imprime PGG&#xD;
Rituximab</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="40" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Status</title>
          <description>0 = Normal activity. Fully active, able to carry on all pre-disease performance without restriction.&#xD;
1 = Symptoms, but ambulatory. Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0 - Fully Active</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 - Restricted</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate</title>
        <description>Overall response rate is percentage of participants with complete (CR) and partial (PR) responses as best response during treatment.&#xD;
CR:&#xD;
Nodal Masses:&#xD;
For FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative&#xD;
For variably FDG-avid or PET negative; regression to normal size on CT.&#xD;
Liver/Spleen:&#xD;
No palpable nodules&#xD;
-Bone Marrow Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative.&#xD;
PR:&#xD;
Nodal Masses:&#xD;
50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes.&#xD;
FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site.&#xD;
Variably FDG-avid or PET negative; regression on CT.&#xD;
Liver/Spleen:&#xD;
50% decrease in SPD of nodules; no increase in size of liver or spleen.&#xD;
Bone Marrow:&#xD;
Irrelevant if positive prior to therapy; cell type should be specified.</description>
        <time_frame>Response assessed at week 14 of study calendar (10 weeks after the 4-week treatment regimen).</time_frame>
        <population>All evaluated participants including two (2) non evaluable (NE) participants with partial or complete response (PR, CR)</population>
        <group_list>
          <group group_id="O1">
            <title>Imprime PGG and Rituximab</title>
            <description>The study drug, Imprime PGG, will be administered intravenously at a dose of 4mg/kg weekly for 4 weeks. Rituximab will be administered intravenously by institutional standards concurrently at a dose of 375mg/m2 weekly for 4 weeks. Response will be assessed with CT scans 10 weeks +/- 3 days following the completion of treatment&#xD;
Imprime PGG&#xD;
Rituximab</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Overall response rate is percentage of participants with complete (CR) and partial (PR) responses as best response during treatment.&#xD;
CR:&#xD;
Nodal Masses:&#xD;
For FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative&#xD;
For variably FDG-avid or PET negative; regression to normal size on CT.&#xD;
Liver/Spleen:&#xD;
No palpable nodules&#xD;
-Bone Marrow Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative.&#xD;
PR:&#xD;
Nodal Masses:&#xD;
50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes.&#xD;
FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site.&#xD;
Variably FDG-avid or PET negative; regression on CT.&#xD;
Liver/Spleen:&#xD;
50% decrease in SPD of nodules; no increase in size of liver or spleen.&#xD;
Bone Marrow:&#xD;
Irrelevant if positive prior to therapy; cell type should be specified.</description>
          <population>All evaluated participants including two (2) non evaluable (NE) participants with partial or complete response (PR, CR)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Patients will be accrued in a single stage design, with a goal accrual of 25 patients.&#xD;
Assuming a 30% response rate with rituximab alone, if the true but unknown rate of CR or PR is 50% with the addition of Imprime PGG, the probability of observing 11 or more patients with a response is 0.79 with 0.098 one-sided type-I error.&#xD;
Therefore a study with 25 patients, in which an observed response rate of 11/25 (44%) would be considered worthy of further consideration.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.044</p_value>
            <method>Fisher Exact</method>
            <param_type>percent</param_type>
            <param_value>48</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>31</ci_lower_limit>
            <ci_upper_limit>66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression-free Survival (PFS)</title>
        <description>Progression free survival (PFS) is defined as the time from start of treatment to disease progression or death from any cause as estimated by Kaplan Meier methods. Patients who have not progressed and are alive are censored at the date the patient is known to be progression-free. Response is measure using the International Harmonization Project for Lymphoma criteria Cheson 2007, using CT scans of the chest, abdomen, and pelvis.</description>
        <time_frame>Patients were followed for a median (range) of 13.6 months (3-25).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imprime PGG and Rituximab</title>
            <description>The study drug, Imprime PGG, will be administered intravenously at a dose of 4mg/kg weekly for 4 weeks. Rituximab will be administered intravenously by institutional standards concurrently at a dose of 375mg/m2 weekly for 4 weeks. Response will be assessed with CT scans 10 weeks +/- 3 days following the completion of treatment&#xD;
Imprime PGG&#xD;
Rituximab</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-free Survival (PFS)</title>
          <description>Progression free survival (PFS) is defined as the time from start of treatment to disease progression or death from any cause as estimated by Kaplan Meier methods. Patients who have not progressed and are alive are censored at the date the patient is known to be progression-free. Response is measure using the International Harmonization Project for Lymphoma criteria Cheson 2007, using CT scans of the chest, abdomen, and pelvis.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" lower_limit="0" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR)</title>
        <description>Duration of response DR is defined as the time from the date of first response (complete or partial) after treatment to the date of disease progression or death for any cause. Patients who are alive without progression are censored at the date the patient is last know to be progression-free.</description>
        <time_frame>Patients were followed for a median (range) of 13.6 months (3-25).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imprime PGG and Rituximab</title>
            <description>The study drug, Imprime PGG, will be administered intravenously at a dose of 4mg/kg weekly for 4 weeks. Rituximab will be administered intravenously by institutional standards concurrently at a dose of 375mg/m2 weekly for 4 weeks. Response will be assessed with CT scans 10 weeks +/- 3 days following the completion of treatment&#xD;
Imprime PGG&#xD;
Rituximab</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR)</title>
          <description>Duration of response DR is defined as the time from the date of first response (complete or partial) after treatment to the date of disease progression or death for any cause. Patients who are alive without progression are censored at the date the patient is last know to be progression-free.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="0" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association of Post-treatment Imprime PGG-bound Neutrophils With Response</title>
        <description>Imprime PGG-bound neutrophils analyzed using established methods (peripheral blood samples and post-treatment tumor samples to quantify the binding of Imprime PGG to neutrophils) combined with treatment response, best response.</description>
        <time_frame>Up to 14 weeks with a median (range of) 13 weeks (12-14).</time_frame>
        <posting_date>09/2021</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 66 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Imprime PGG and Rituximab</title>
          <description>The study drug, Imprime PGG, will be administered intravenously at a dose of 4mg/kg weekly for 4 weeks. Rituximab will be administered intravenously by institutional standards concurrently at a dose of 375mg/m2 weekly for 4 weeks. Response will be assessed with CT scans 10 weeks +/- 3 days following the completion of treatment&#xD;
Imprime PGG&#xD;
Rituximab</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <description>Joint pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Caron A. Jacobson, MD</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617-632-6404</phone>
      <email>cajacobson@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

